Acute Myelogenous Leukemia

Differentiating between acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) in adults is crucial for effective treatment. While both present with similar symptoms like fatigue, bleeding, and infections, key distinctions lie in cell morphology and immunophenotyping. AML blasts typically exhibit Auer rods and myeloid lineage markers (CD13, CD33, CD117, etc.) on flow cytometry. ALL blasts, on the other hand, often express lymphoid lineage markers (CD19, CD20, CD3, etc.). Cytogenetic analysis plays a significant role, identifying specific chromosomal abnormalities associated with each disease, such as the Philadelphia chromosome in ALL. These diagnostic factors directly inform treatment strategies, with AML typically treated with intensive chemotherapy regimens like the 7+3 induction therapy (cytarabine and an anthracycline), while ALL treatment often incorporates targeted therapies like tyrosine kinase inhibitors in addition to chemotherapy. Accurate and rapid diagnosis is essential for optimizing treatment outcomes. Explore how advancements in molecular diagnostics are refining risk stratification and personalized treatment approaches in both AML and ALL.

The 2022 WHO update introduces important refinements to the classification of AML, impacting both diagnostic workup and risk stratification. The update incorporates new provisional entities like myeloid neoplasms with germline predisposition and expands the role of molecular markers in defining specific subtypes, such as AML with NPM1 mutation. This necessitates a more comprehensive molecular diagnostic approach, including next-generation sequencing, to fully characterize the genomic landscape of AML. Furthermore, the updated classification refines risk stratification by incorporating these new molecular markers and cytogenetic abnormalities, allowing for more precise prognostication and individualized treatment decisions. For example, the inclusion of measurable residual disease (MRD) assessment post-treatment further refines risk and can guide decisions regarding allogeneic stem cell transplantation. Consider implementing the updated WHO criteria into your practice to ensure accurate diagnosis and personalized treatment strategies for AML patients. Learn more about integrating these changes into your institutional diagnostic algorithms.

Relapsed or refractory AML presents significant therapeutic challenges, often characterized by drug resistance and persistent MRD. Emerging therapeutic strategies aim to overcome these hurdles through various mechanisms. Targeted therapies, such as FLT3 inhibitors (e.g., gilteritinib, midostaurin) and IDH1/2 inhibitors (e.g., enasidenib, ivosidenib), are showing promise in specific AML subtypes. Immunotherapeutic approaches, including checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy, are being explored to harness the power of the immune system to eliminate leukemic cells. Novel antibody-drug conjugates and other targeted therapies are also under development. These strategies aim not only to induce remission but also to deepen responses and eradicate MRD, improving long-term outcomes. Further research is ongoing to optimize combination therapies and identify predictive biomarkers for response. Explore the latest clinical trial data on emerging therapies and consider how these advancements can inform your treatment approach for patients with relapsed or refractory AML.